Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic